As reported by other groups, aticaprant as a selective and short-acting KOR antagonist, does not display any sedative activity or cause “depression or dysphoria” in rodents as found with classic KOP-r agonists and has recently been under development for new clinical implications as anti- depressant [11,15,23]. Here, OPRK1 is linked to depressive symptom measurement.